Healthcare
INVO Bioscience Reports Strong Revenue Growth in Q4 2023
Fertility Company Achieves Significant Expansion in Clinic Revenue INVO Bioscience (INVO) has released its financial results for the fourth quarter...
Vanda Pharmaceuticals Rejects Unsolicited Acquisition Proposals from Future Pak
Board Determines Offers Undervalue Company's Robust Growth Prospects Vanda Pharmaceuticals (VNDA) has confirmed receiving multiple unsolicited acquisition proposals from Future...
Palisade Bio Reports Promising Results for UC Treatment PALI-2108
Successful Analysis Demonstrates Effective Bioactivation of Colon-Specific PDE4 Inhibitor Prodrug Palisade Bio (PALI), a biopharmaceutical firm dedicated to advancing therapies...
PaxMedica Completes Milestone for Suramin IV Formulation, Nears FDA Submission
Biopharmaceutical Company Advances Potential Treatment for Fatal Tropical Disease and Autism Spectrum Disorder PaxMedica (PXMD) has achieved a significant milestone...
Candel Therapeutics’ CAN-2409 Receives FDA Orphan Drug Designation for Pancreatic Cancer
Milestone Achievement Enhances Development Efforts for Multimodal Biological Immunotherapy Candel Therapeutics (CADL) has achieved a significant milestone in its fight...
Rallybio Collaborates with Johnson & Johnson to Tackle Rare Disease FNAIT
Partnership Aims to Develop Therapeutic Solutions for Fetal and Neonatal Alloimmune Thrombocytopenia Rallybio Corporation (RLYB) has announced a collaboration with...
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences in $4.9 Billion Deal
Acquisition Strengthens Vertex's Position in Immunotherapy and Renal Disease Treatment Vertex Pharmaceuticals (VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN)...
Advancing Addiction Treatment: Adial Pharmaceuticals’ AD04 Shows Promise in Clinical Study
Peer-Reviewed Article Highlights Safety and Efficacy of Low-Dose Ondansetron in Treating Alcohol Use Disorder Adial Pharmaceuticals (ADIL), a pioneer in...
Moderna’s Cancer Vaccine Shows Positive Results, Shares Surge
Early-Stage Trial Signals Potential Breakthrough in Cancer Treatment Moderna (MRNA) witnessed a significant uptick in its shares, climbing 8% to...
Acrivon Therapeutics Secures $130 Million in Private Financing for Precision Oncology Advancements
Biopharmaceutical Company Raises Capital to Propel Clinical Trials and Innovative Research Acrivon Therapeutics (ACRV), a pioneer in precision oncology medicines,...
